Aberrant peripheral blood CD4+ CD25+ FOXP3+ regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma

Dehghani, Mehdi; Kalani, Mehdi; Golmoghaddam, Hossein; Ramzi, Mani; Arandi, Nargess

doi:10.1007/s00262-020-02591-y

Cited by 16 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Th17 cells produce inflammatory cytokines such as IL17A and IL17F to trigger an inflammatory response [ 37 , 38 ]. Despite mediating anti-tumor responses through recruiting immune cells into tumors, activating effector CD8 + T cells, and promoting Th1 polarization, Th17 cells activate angiogenesis and immunosuppressive activities, leading to tumor progression in some models [ 38 ].…”

Section: Cd4 + T Cellsmentioning

confidence: 99%

“…Tregs are a specialized subgroup of CD4 + T cells that are identified either as CD4 + CD25 + [ 42 ] or as CD4 + CD25 + FOXP3 + cells, and whose main functions are to regulate immune responses by suppressing the activation of other CD4 + T cell subsets [ 20 , 37 ], and to preserve self-tolerance. However, they also promote tumor progression through a variety of molecules such as CTLA4, IL2, and IL10 [ 16 ].…”

Section: Cd4 + T Cellsmentioning

confidence: 99%

“…HRS cells immune escape is facilitated by the protective shield conferred by CD4 + cells rosetting around tumor cells and by polarization towards Tregs [ 43 ]. Some researchers have found that high levels of Tregs in cHL tissues are not associated with an adverse prognosis [ 21 ], whereas others have found fewer Tregs in relapsed patients [ 14 , 37 ] and a positive association between them and survival [ 2 , 5 , 23 , 37 , 42 ]. All these findings are counter to what has been seen in other tumors [ 27 ], in which Treg depletion leads to tumor regression [ 2 ].…”

Section: Cd4 + T Cellsmentioning

confidence: 99%

See 2 more Smart Citations

The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good

Menéndez

Solórzano

Fernández

et al. 2022

Cancers

View full text Add to dashboard Cite

The classic Hodgkin lymphoma (cHL) tumor microenvironment (TME) is by far the most abundant component of tumors and is responsible for most of their biological and clinical characteristics. Recent advances in our knowledge of these networks in cellular interactions allow us to understand that the neoplastic Hodgkin and Reed Sternberg (HRS) cells, although they are in the minority, are the main architects of this dysregulated immune milieu. Here, we review the major changes that have happened in recent years: from TME as a helpless bystander, reflecting an ineffective immune response, to a dynamic tumor-promoting and immunosuppressive element. The HRS cells promote survival through interconnected intrinsic and extrinsic alterations, boosting pro-tumoral signaling pathways through genetic aberrations and autocrine growth signals, in parallel with abnormal cytokine secretion for the recruitment and selection of the best cell partners for this immunosuppressive TME. In turn, cHL is already proving to be the perfect model with which to address an immune checkpoint blockade. Preliminary data demonstrate the utility of druggable key signaling pathways in this ensemble, such as JAK-STAT, NF-κB, and others. In addition, myriad biomarkers predicting a response await validation by new in situ multiplex analytical methods, single-cell gene expression, and other techniques. Together, these components will define the functional phenotypes with which we will elucidate the molecular pathogenesis of the disease and improve the survival of patients who are refractory to conventional therapies.

show abstract

Section: Cd4 + T Cellsmentioning

confidence: 99%

Section: Cd4 + T Cellsmentioning

confidence: 99%

Section: Cd4 + T Cellsmentioning

confidence: 99%

See 1 more Smart Citation

The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good

Menéndez

Solórzano

Fernández

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…In the study by Kusano and colleagues, low CD4+ T-cell count at diagnosis was significantly related to OS and PFS, and the CD4+ T-cell count might be an independent predictive marker in patients with DLBCL ( 25 ). Dehghani et al ( 26 ) also demonstrated that in patients with DLBCL receiving R-CHOP, the elevated level of Treg cell was associated with improved prognosis. Therefore, the amounts of peripheral hematologic cells can reflect the inflammatory and immune changes.…”

Section: Discussionmentioning

confidence: 97%

Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma

et al. 2021

View full text Add to dashboard Cite

ObjectiveThe systemic immune-inflammation index (SII) based on neutrophil, platelet and lymphocyte counts, is a prognostic biomarker in some solid cancers. However, the prognostic value of SII has not yet been validated. This study was to evaluate the role of SII in predicting survival for patients with diffuse large B cell lymphoma (DLBCL).MethodsWe retrospectively investigated 224 patients with DLBCL between August 2005 and October 2018. Kaplan–Meier analysis and Cox proportional hazard models were used to assess the prognostic value of SII.ResultsIn the ROC curve analysis, SII had the highest AUC and was more accurate as a prognostic factor. Patients with higher SII tended to have higher level of LDH, more advanced stage, poor PS, and high IPI score compared with low SII group. In univariate analyses, SII, PLR and NLR were all prognostic for progression-free survival and overall survival. Moreover, only SII, older age, HBSAg-positive and IPI were the independent prognostic factors for patients in multivariate analysis. The nomogram based on SII, older age, HBSAg status and IPI showed accurate prognostic ability for predicting 3-years and 5-years survival rates (c-index, 0.791) compared to the IPI alone (c-index, 0.716).ConclusionSII was a powerful tool for predicting outcome in patients with DLBCL. It might assist the separation of high-risk patients among patients with the same IPI.

show abstract

“…Foxp3+ Treg is the activated form of Treg. Foxp3+ Treg becomes an important infection tolerance regulator by transforming conventional CD4+ foxp3− T cells (Tconv cells) into induced CD4+ Foxp3+ (Dehghani et al, 2020). Treg is directly produced by suppressive cytokines, such as IL-10, TGF-β, and IL-35, or indirectly produced through activating dendritic cells.…”

Section: Future Expectationmentioning

confidence: 99%

The Role of IL-35 in the Pathophysiological Processes of Liver Disease

Lian

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

It is known that liver diseases have several characteristics of massive lipid accumulation and lipid metabolic disorder, and are divided into liver inflammation, liver fibrosis, liver cirrhosis (LC), and hepatocellular carcinoma (HCC) in patients. Interleukin (IL)-35, a new-discovered cytokine, can protect the liver from the environmental attack by increasing the ratio of Tregs (T regulatory cells) which can increase the anti-inflammatory cytokines and inhibit the proliferation of immune cellular. Interestingly, two opposite mechanisms (pro-inflammatory and anti-inflammatory) have connection with the ultimate formation of liver diseases, which suggest that IL-35 may play crucial function in the process of liver diseases through immunosuppressive regulation. Besides, some obvious advantages also imply that IL-35 can be considered as a new therapeutic target to control the progression of liver diseases, while its mechanism of function still needs further research.

show abstract

Aberrant peripheral blood CD4+ CD25+ FOXP3+ regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma

Cited by 16 publications

References 28 publications

The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good

The Hodgkin Lymphoma Immune Microenvironment: Turning Bad News into Good

Prognostic Significance of Systemic Immune-Inflammation Index in Patients With Diffuse Large B-Cell Lymphoma

The Role of IL-35 in the Pathophysiological Processes of Liver Disease

Contact Info

Product

Resources

About